We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against the other best biotech penny stocks to invest in now.
Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks. In a recent note to clients, John Flood, Goldman’s Head of Americas Equities Sales Trading, highlighted biotech as an under-the-radar opportunity for those seeking to capitalize on the Fed’s rate cuts. Flood noted that biotechnology stocks are uniquely sensitive to changes in interest rates as they often rely on projected future profits and are heavily impacted by the cost of capital. With little or no current profitability but significant upside potential, if clinical trials succeed, these stocks have an “option-like structure” that makes them particularly responsive to interest rate movements.
The note also emphasized that biotech has recently seen improved fundamentals driven by positive clinical outcomes and a more favorable regulatory environment. Despite these tailwinds, biotech remains under-owned by hedge funds. According to Goldman’s data, the sector ranks in the 13th percentile in hedge fund long/short positioning over the past year and just the 4th percentile over the past five years.
Recent performance data supports Goldman’s outlook. The iShares Biotech ETF climbed 7.7% in Q3, outperforming the Nasdaq Biotech Index and more than doubling the S&P 500’s 3.2% gain over the same period. For investors anticipating a continued decline in bond yields, Goldman suggests biotechnology stocks may offer more attractive exposure compared to other rate-sensitive equity sectors, which are more dependent on broader economic growth trends.
READ ALSO: 12 Best Technology Penny Stocks To Buy According to Hedge Funds and 12 Best Energy Stocks To Invest In Now.
Biotech Innovations: Small Caps Lead the Way
In an interview with Yahoo Finance on October 30, Stacey Sears, Portfolio Manager at Emerald Advisers, provided a comprehensive overview of the current landscape and investment opportunities in small and emerging biotechnology companies.
Sears acknowledged that there has been a significant innovation in the healthcare industry, especially over the past 20 to 30 years, which was catalyzed after the decoding of the human genome in 2003, as it identified over 8,000 genetic diseases. This breakthrough provided a roadmap for researchers and scientists, leading to accelerated innovation in areas such as DNA and RNA editing and the development of treatments for orphan and rare diseases.
Sears noted that small and emerging biotechnology companies have been at the forefront of this innovation. In 2023, approximately two-thirds of all clinical trials were initiated by small and emerging biotechnology firms, and about 56% of new drug substances approved by regulatory bodies originated from these smaller companies.
Sears pointed out that the sector has been underperforming over the past couple of years. This underperformance is largely due to the inverse correlation between healthcare stocks and interest rates and yields. However, she noted that the sector is now starting to see a favorable shift. Clinical advancements have continued unabated, and the pipeline of new treatments and drugs remains robust. Large pharmaceutical companies are facing a patent cliff, estimated to be around $30 billion by the end of this decade as their drugs become generic. Small and emerging biotechnology companies are seen as key sources for filling this pipeline. This situation is creating a potential M&A tailwind, as larger companies look to acquire innovative smaller firms to bolster their drug pipelines.
The biotechnology sector presents a unique investment opportunity, driven by favorable interest rates, ongoing clinical advancements, and increased M&A activity. Small and emerging biotech firms, in particular, are poised to play a critical role in addressing unmet medical needs and fueling innovation in the healthcare space.
A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory.
Our Methodology
To compile our list of the 12 best biotech penny stocks to invest in now, we used Finviz and Yahoo stock screeners to find the 30 largest biotechnology companies trading below the price of $5 as of December 26. We then used Insider Monkey’s Hedge Fund database to rank 12 stocks according to the largest number of hedge fund holders, as of Q3 2024. The list is sorted in ascending order of hedge fund sentiment.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Nuvation Bio Inc. (NYSE:NUVB)
Number of Hedge Fund Investors: 34
Stock Price as of December 26: $2.82
Nuvation Bio Inc. (NYSE:NUVB) is a clinical biopharmaceutical company dedicated to the development of innovative therapies for patients with significant unmet medical needs, particularly in oncology. The company’s primary focus is on the development of targeted therapies for genetically defined cancers, with a current pipeline that includes Taletrectinib, a ROS1 inhibitor, and Safusidenib, a potential treatment for Diffuse IDH1-mutant glioma.
Nuvation Bio Inc. (NYSE:NUVB) is positioning itself for significant growth through a combination of strategic clinical development, regulatory milestones, and commercial readiness. The company’s lead candidate, Taletrectinib, is a key driver of this growth strategy. Taletrectinib is currently in two pivotal Phase 2 trials, TRUST-I and TRUST-II, targeting advanced ROS1-positive non-small cell lung cancer (NSCLC). The pooled data from these trials, presented at the European Society for Medical Oncology (ESMO) in September, demonstrated impressive outcomes that are notably superior to those of existing ROS1 inhibitors, such as crizotinib, entrectinib, and repotrectinib, positioning Taletrectinib as a potential best-in-class therapy.
On December 23, Nuvation Bio Inc. (NYSE:NUVB) achieved a significant regulatory milestone with the FDA’s acceptance of its New Drug Application (NDA) for Taletrectinib, which was granted Priority Review. The FDA has set a target action date of June 23, 2025, for the application, and Taletrectinib has already been awarded Orphan Drug and Breakthrough Therapy Designations by the agency.
To further enhance its competitive position, Nuvation Bio Inc. (NYSE:NUVB) is also advancing its second lead candidate, Safusidenib, which is currently in a Phase 2 trial for the treatment of Diffuse IDH1-mutant glioma.
In preparation for the potential approval and commercial launch of Taletrectinib, Nuvation Bio Inc. (NYSE:NUVB) is building a strong commercial infrastructure. This includes establishing a specialized sales force, developing comprehensive patient support programs, and forming strategic partnerships with key stakeholders in the oncology community. Nuvation Bio Inc. (NYSE:NUVB) is also actively exploring other potential indications for both Taletrectinib and Safusidenib, which could further expand their market reach and commercial potential.
Overall, NUVB ranks 1st on our list of best biotech penny stocks to invest in now. While we acknowledge the potential of NUVB to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
